Bitget celebrates its 8th anniversary with a $3 million trading competition and a $50,000 community reward pool, highlighting its growth into a Universal Exchange (UEX) that combines cryptocurrencies, stocks, commodities, forex, options, and CFDs. The platform recently expanded its proof-of-reserves coverage to over 20 digital assets, reporting a 122% reserve ratio in August. Bitget's anniversary campaign includes trading story contests and VIP tier upgrades, reflecting its strategy to integrate traditional and digital financial products under one platform. The exchange serves 125 million users globally and plans further AI and institutional service developments.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
